Search

Your search keyword '"Al-Lazikani, Bissan"' showing total 365 results

Search Constraints

Start Over You searched for: Author "Al-Lazikani, Bissan" Remove constraint Author: "Al-Lazikani, Bissan"
365 results on '"Al-Lazikani, Bissan"'

Search Results

1. The Lancet Commission on prostate cancer: planning for the surge in cases

4. Supplementary Figure 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

5. Supplementary Figure 12 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

6. Data from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

7. Supplementary Figure 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

8. Supplementary Figure 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

9. Supplementary Table 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

10. Supplementary Figure 9 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

11. Supplementary Table 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

12. Supplementary Table 1 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

13. Supplementary Table 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

14. Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

15. Supplementary Materials and Methods from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

16. Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

17. Supplementary Figure 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

18. Supplementary Table 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

19. Supplementary Table 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

20. Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

21. Supplementary Figure 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

23. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets

24. Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.

26. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

30. Supplementary Figure from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

31. Data from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

32. Supplementary Table from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

33. Supplementary Tables S1-S4 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

34. Supplementary Note from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

35. Supplementary Figures S1-S3 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

36. Supplementary Data from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

41. Supplementary Figure from JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer

42. Data from JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer

43. Supplementary Table from JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer

45. canSAR: update to the cancer translational research and drug discovery knowledgebase

46. R-loop editing by DNA cytosine deaminase APOBEC3B determines the activity of estrogen receptor enhancers

47. The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use

48. Targeting the BAG-1 family of co-chaperones in lethal prostate cancer

49. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates

50. Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Catalog

Books, media, physical & digital resources